Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms

Prostate

Volumn 54, Issue 3, 2003, Pages 194-205

  Wang, Hui ^a   Yu, Dong ^b   Agrawal, Sudhir ^b   Zhang, Ruiwen ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b HYBRIDON INC   (United States)

Author keywords

5 fluorouracil; Chemotherapy; Irinotecan; P53; Paclitaxel; Prostate cancer xenograft

Indexed keywords

10 HYDROXYCAMPTOTHECIN; ANTISENSE OLIGONUCLEOTIDE; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; PACLITAXEL; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; RITUXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RAT STRAIN; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FLUOROURACIL; GENE THERAPY; HUMANS; MALE; MICE; MICE, NUDE; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037441417     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10187     Document Type: Article

References (50)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2002;52:23-47.
2. Stephan C, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 2002;59:2-8.
3. Schroder FH. Prostate cancer: Natural history and surgical treatment of localised disease. Eur J Cancer 2001;37:S127-S136.
4. Morris MJ, Scher HI. Novel therapies for the treatment of prostate cancer: Current clinical trials and development strategies. Surg Oncol 2002;11:13-23.
5. Ross JS, Sheehan CE, Fisher HA, Kauffman RA, Dolen EM, Kallakury BV. Prognostic markers in prostate cancer. Expert Rev Mol Diagn 2002;2:129-142.
6. Trapman J. Molecular mechanisms of prostate cancer. Eur J Cancer 2001;37:S119-S125.
7. Lissbrant IF, Lissbrant E, Damber JE, Bergh A. Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 2001;35:437-452.
8. Mason MD, Davies G, Jiang WG. Cell adhesion molecules and adhesion abnormalities in prostate cancer. Crit Rev Oncol Hematol 2002;41:11-28.
9. Ross JS, Sheehan CE, Dolen EM, Kallakury BV. Morphologic and molecular prognostic markers in prostate cancer. Adv Anat Pathol 2002;9:115-128.
10. Prives C, Hall PA. The p53 pathway. J Pathol 1999;187:112-126.
11. Tamboli P, Amin MB, Xu HJ, Linden MD. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: Comparison with prostatic adenocarcinoma and benign prostate. Mod Pathol 1998;11:247-252.
12. Stackhouse GB, Sesterhenn IA, Bauer JJ, Mostofi FK, Connelly RR, Srivastava SK, Moul JW. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 1999;162:2040-2045.
13. Takayama H, Shin M, Nonomura N, Okuyama A, Aozasa K. p53 mutations in prostatic intraepithelial neoplasia and concurrent carcinoma:analysis of laser capture microdissected specimens from non-transition and transition zones. Jpn J Cancer Res 2000;91:941-947.
14. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
15. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-852.
16. Di Leonardo A, Linke SP, Clarkin K, Wahl GM. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Gene Dev 1994;8:2540-2551.
17. Kuerbits SJ, Plundett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-7495.
18. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm2 autoregulatory feedback loop. Genes Dev 1993;7:1126-1132.
19. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Volgelstein B. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-1174.
20. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991;10:1565-1569.
21. Lundgren K, Montes de Oca Luna R, Mcneill YB, Emerick EP, Spencer B, Barfield CR, Lozano G, Rosenberg MP, Finlay CA. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 1997;11:714-725.
22. Zhang R, Wang H. MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Design 2000;6:393-416.
23. Ittmann M, Wieczorek R, Heller P, Dave A, Prover J, Krolewski J. Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol 1994;145:287-293.
24. Gao X, Porter AT, Honn KV. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications. Adv Exp Med Biol 1997;407:41-53.
25. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, CordonCardo C. Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression. Clin Cancer Res 1999;5:2082-2088.
26. Leite KR, Franco MF, Srougi M, Nesrallah LJ, Nesrallah A, Bevilacqua RG, Darini E, Carvalho CM, Meirelles MI, Santana I, Camara-Lopes LH. Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol 2001;14:428-436.
27. Chen CY, Oliner JD, Zhan Q, Fornace AJ, Jr, Vogelstein B, Kastan MB. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 1994;91: 2684-2688.
28. Chen J, Wu X, Lin J, Levine AJ. Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 1996;16:2445-2452.
29. Chen J, Lin J, Levine AJ. Regulation of transcription functions of the p53 tumor suppressor by the mdm2 oncogene. Mol Med 1995;1:142-152.
30. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-299.
31. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by mdm2. Nature 1997;387:299-303.
32. Taj MM, Tawil RJ, Engstrom LD, Zeng Z, Hwang C, Sanda MG, Wechsler DS. Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells. Prostate 2001;47:194-204.
33. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI. Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 1999;91:1869-1876.
34. Zamecnik PC. History of antisense oligonucleotides. In: Agrawal S, editor. Antisense therapeutics. Totowa: Humana Press; 1996. p 1-12.
35. Wang H, Prasad G, Buolamwini JK, Zhang R. Antisense anticancer oligonucleotide therapeutics. Curr Cancer Drug Targets 2001;1:177-196.
36. Chen L, Agrawal S, Zhou W, Zhang R, Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA 1998;95:195-200.
37. Wang H, Oliver P, Zeng X, Chen J, Chen L, Zhou W, Agrawal S, Zhang R. MDM2 oncogene as a target for cancer therapy: An antisense approach. Int J Oncol 1999;15:653-660.
38. Chen L, Lu W, Agrawal S, Zhou W, Zhang R, Chen J. Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. Mol Med 1999;5:21-34.
39. Wang H, Nan L, Yu D, Agrawal S, Zhang R. Antisense antiMDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: In vitro and in vivo activities and mechanisms. Clin Cancer Res 2001;7:3613-3624.
40. Wang H, Wang S, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms. Intl J Oncol 2002;20:745-752.
41. Prasad G, Wang H, Agrawal S, Zhang R. Antisense anti-MDM2 oligonucleotides as a novel spproach to the treatment of glioblastoma multiforme. Anticancer Res 2002;22:107-116.
42. Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R. Antitumor efficacy of a novel antisense anti-mdm2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms. Mol Med 2002;8:185-199.
43. Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, Channavajjala L, Saxinger C, Zhang R. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc Natl Acad Sci USA 1997;94:2620-2625.
44. Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R. Anti-tumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to RI α-subunit of protein kinase A after oral administration. Proc Natl Acad Sci USA 1999;96:13989- 13994.
45. Lane DP, Lain S. Therapeutic exploitation of the p53 pathway. Trend Mol Med 2002;8:S38-S42.
46. Bottger A, Bottger V, Sparks A, Liu WL, Howard SF, Lane DP. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 1997;7:860-869.
47. Bottger A, Bottger A, Garcia EC, Garcia-Echeverria C, Chene P, Hochkeppel H-K, Smapson W, Ang K, Howard SF, Picksley SM, Lane DP. Molecular characterization of the hdm2-p53 interaction. J Mol Biol 1997;269:744-756.
48. Juven-Gershon T, Oren M. Mdm2: The ups and downs. Mol Med 1999;5:71-83.
49. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine A. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 1993;8:2353-2360.
50. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer. Nature Med 1996;2:912-917.